Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#181 / 200 Total
SCWO - 374Water Inc - Stock Price Chart
TickerSCWO [NASD, RUT]
Company374Water Inc
CountryUSA
IndustryPollution & Treatment Controls
Market Cap176.53MEPS (ttm)-0.05
P/E-EPS this Y-33.33%
Forward P/E-EPS next Y25.00%
PEG-EPS past 5Y-23.79%
P/S106.99EPS next 5Y-
P/B16.56EPS Q/Q-71.32%
Dividend-Sales Q/Q-95.41%
Insider Own52.72%Inst Own12.03%
Insider Trans0.00%Inst Trans5.03%
Short Float5.57%EarningsAug 15/b
Analyst Recom1.00Target Price2.50
Avg Volume133.18K52W Range0.83 - 2.09
374Water, Inc. is a clean technology company. It offers supercritical water oxidation (SWCO) waste processors. It caters to municipal and industrial wastewater treatment plants, food waste, chemical plants, and army camps and emergency situations. The company was founded by Yaacov Nagar and Marc Deshusses on September 8, 2005 and is headquartered in Durham, NC.
BRNS - Barinthus Biotherapeutics Plc. ADR - Stock Price Chart
TickerBRNS [NASD]
CompanyBarinthus Biotherapeutics Plc. ADR
CountryUnited Kingdom
IndustryBiotechnology
Market Cap52.11MEPS (ttm)-1.65
P/E-EPS this Y10.83%
Forward P/E-EPS next Y4.82%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.33EPS Q/Q30.16%
Dividend-Sales Q/Q-100.00%
Insider Own7.52%Inst Own17.81%
Insider Trans0.00%Inst Trans2.25%
Short Float0.02%EarningsAug 08/b
Analyst Recom1.00Target Price7.25
Avg Volume20.32K52W Range1.11 - 5.10
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
PRCH - Porch Group Inc - Stock Price Chart
TickerPRCH [NASD, RUT]
CompanyPorch Group Inc
CountryUSA
IndustrySoftware - Application
Market Cap146.80MEPS (ttm)-0.87
P/E-EPS this Y28.66%
Forward P/E-EPS next Y19.13%
PEG-EPS past 5Y-
P/S0.31EPS next 5Y-
P/B-EPS Q/Q28.61%
Dividend-Sales Q/Q12.23%
Insider Own35.06%Inst Own54.25%
Insider Trans-0.04%Inst Trans1.10%
Short Float15.30%EarningsAug 06/a
Analyst Recom1.67Target Price3.50
Avg Volume1.01M52W Range0.50 - 4.78
Porch Group, Inc. engages in the development and operation of a vertical software platform. It provides software solutions to home service companies such as home inspectors, moving companies, real estate agencies, utility companies, and warranty companies. The company was founded by Matt Ehrlichman & Ronnie Castro in 2011 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tabak ShawnCHIEF FINANCIAL OFFICERJun 06 '24Sale2.0215,00030,305295,142Jun 10 06:51 PM
Tabak ShawnCHIEF FINANCIAL OFFICERMar 26 '24Sale4.0419,04076,956292,311Mar 28 05:25 PM
Tabak ShawnCHIEF FINANCIAL OFFICERMar 20 '24Sale3.8630,282116,796337,029Mar 22 07:11 PM
Tabak ShawnCHIEF FINANCIAL OFFICERMar 21 '24Sale4.0025,678102,743311,351Mar 22 07:11 PM
Velasquez CamillaDirectorDec 15 '23Buy2.531,9694,98245,218Dec 19 05:06 PM
CRVS - Corvus Pharmaceuticals Inc - Stock Price Chart
TickerCRVS [NASD]
CompanyCorvus Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap352.78MEPS (ttm)-0.45
P/E-EPS this Y26.34%
Forward P/E-EPS next Y-20.61%
PEG-EPS past 5Y19.89%
P/S-EPS next 5Y-
P/B6.89EPS Q/Q47.85%
Dividend-Sales Q/Q-
Insider Own19.87%Inst Own27.89%
Insider Trans5.05%Inst Trans-
Short Float3.27%EarningsAug 06/a
Analyst Recom1.50Target Price10.12
Avg Volume384.66K52W Range1.05 - 6.15
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones William BentonSee RemarksMay 06 '24Buy1.7320,00034,624153,773May 07 05:06 PM
MILLER RICHARD A MDPresident and CEOMay 06 '24Buy1.73577,6341,000,000577,634May 07 05:05 PM
NNBR - NN Inc - Stock Price Chart
TickerNNBR [NASD, RUT]
CompanyNN Inc
CountryUSA
IndustryConglomerates
Market Cap200.70MEPS (ttm)-1.14
P/E-EPS this Y45.98%
Forward P/E-EPS next Y91.49%
PEG-EPS past 5Y30.43%
P/S0.42EPS next 5Y15.00%
P/B1.85EPS Q/Q67.34%
Dividend-Sales Q/Q-1.77%
Insider Own12.38%Inst Own64.26%
Insider Trans-3.03%Inst Trans13.89%
Short Float4.68%EarningsAug 07/a
Analyst Recom1.00Target Price6.67
Avg Volume125.76K52W Range1.62 - 5.40
NN, Inc. engages in the design and manufacture high-precision components and assemblies primarily for the electrical, automotive, general industrial, aerospace and defense, and medical markets. It operates through the Mobile Solutions and Power Solutions segments. The Mobile Solutions segment manufactures system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors. The Power Solutions segment designs and produces a broad range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control, and for military devices. The company was founded by Richard D. Ennen in October 1980 and is headquartered in Charlotte, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENVENUTI RAYNARD D.DirectorAug 19 '24Buy3.7410,00037,400301,104Aug 21 04:07 PM
HARMAN JERI JDirectorAug 16 '24Buy3.646,84924,930308,265Aug 19 04:12 PM
Carroll ChristinaDirectorAug 16 '24Buy3.515,70220,013266,999Aug 19 04:10 PM
Faria Joao VDirectorAug 14 '24Buy3.4120,00068,200277,843Aug 16 04:12 PM
BENVENUTI RAYNARD D.DirectorMay 29 '24Sale3.14236,104741,3670May 31 04:19 PM
IOVA - Iovance Biotherapeutics Inc - Stock Price Chart
TickerIOVA [NASD, RUT]
CompanyIovance Biotherapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap3.17BEPS (ttm)-1.68
P/E-EPS this Y31.97%
Forward P/E-EPS next Y44.22%
PEG-EPS past 5Y-8.25%
P/S96.88EPS next 5Y-
P/B4.05EPS Q/Q28.17%
Dividend-Sales Q/Q12969.75%
Insider Own18.58%Inst Own68.00%
Insider Trans0.00%Inst Trans10.42%
Short Float24.40%EarningsAug 08/a
Analyst Recom1.50Target Price22.90
Avg Volume6.37M52W Range3.21 - 18.33
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vogt Frederick GInterim CEO & General CounselSep 03 '24Option Exercise0.0057,2920212,175Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerSep 03 '24Option Exercise0.0027,345071,233Sep 05 07:54 PM
BILINSKY IGORChief Operating OfficerSep 03 '24Option Exercise0.0026,954066,313Sep 05 07:53 PM
Bellemin Jean-MarcChief Financial OfficerSep 03 '24Option Exercise0.0023,438041,239Sep 05 07:52 PM
Vogt Frederick GInterim CEO & General CounselJul 15 '24Option Exercise0.0020,8350168,160Jul 17 08:01 PM
FBLG - FibroBiologics Inc - Stock Price Chart
TickerFBLG [NASD, RUT]
CompanyFibroBiologics Inc
CountryUSA
IndustryBiotechnology
Market Cap99.85MEPS (ttm)-0.64
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q117.98%
Dividend-Sales Q/Q-
Insider Own23.65%Inst Own9.60%
Insider Trans0.22%Inst Trans-
Short Float6.89%EarningsAug 28
Analyst Recom1.00Target Price13.00
Avg Volume430.50K52W Range1.08 - 55.00
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'HEERON PETEChief Executive OfficerAug 12 '24Buy1.918,50016,2696,056,647Aug 12 09:58 PM
Khoja HamidChief Scientific OfficerAug 12 '24Buy1.9010,00019,00011,250Aug 12 09:58 PM
SOFI - SoFi Technologies Inc - Stock Price Chart
TickerSOFI [NASD]
CompanySoFi Technologies Inc
CountryUSA
IndustryCredit Services
Market Cap8.94BEPS (ttm)-0.23
P/E-EPS this Y129.27%
Forward P/E32.59EPS next Y144.39%
PEG-EPS past 5Y32.14%
P/S2.63EPS next 5Y-
P/B1.51EPS Q/Q112.20%
Dividend-Sales Q/Q27.14%
Insider Own4.97%Inst Own38.04%
Insider Trans-27.29%Inst Trans-1.03%
Short Float18.42%EarningsOct 29/b
Analyst Recom2.94Target Price8.14
Avg Volume41.37M52W Range6.01 - 10.49
SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It offers home loans, personal loans, and credit cards. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment includes personal loan, student loan, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Keough KelliEVP, GBUL, SIPSSep 23 '24Sale7.999,30874,343161,511Sep 24 06:23 PM
Rishel JeremyChief Technology OfficerSep 20 '24Sale8.1268,081552,818521,505Sep 24 06:22 PM
Kelli Allen KeoughAffiliateSep 23 '24Proposed Sale8.0528,206227,058Sep 23 04:03 PM
Rishel JeremyOfficerSep 20 '24Proposed Sale8.1268,061552,655Sep 20 10:11 AM
White Derek JOfficerSep 17 '24Proposed Sale8.1861,643504,289Sep 17 04:31 PM
TELA - TELA Bio Inc - Stock Price Chart
TickerTELA [NASD]
CompanyTELA Bio Inc
CountryUSA
IndustryMedical Devices
Market Cap66.72MEPS (ttm)-1.72
P/E-EPS this Y28.13%
Forward P/E-EPS next Y21.82%
PEG-EPS past 5Y5.17%
P/S1.03EPS next 5Y-
P/B23.21EPS Q/Q-10.04%
Dividend-Sales Q/Q11.02%
Insider Own32.60%Inst Own59.53%
Insider Trans-5.05%Inst Trans3.15%
Short Float10.22%EarningsAug 12/a
Analyst Recom1.00Target Price10.80
Avg Volume211.95K52W Range2.32 - 7.84
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerJun 28 '24Sale4.74378,0001,791,7202,457,542Jul 02 04:54 PM
ORBIMED ADVISORS LLC10% OwnerJul 02 '24Sale4.5436,600166,1642,407,242Jul 02 04:54 PM
ORBIMED ADVISORS LLC10% OwnerJul 01 '24Sale4.6813,70064,1162,443,842Jul 02 04:54 PM
Firestone Gregory A.Chief Business OfficerDec 05 '23Buy5.652,60014,68835,511Dec 07 04:02 PM
Cuca RobertoCOO and CFONov 14 '23Buy4.4910,00044,93862,371Nov 14 08:02 PM
LAC - Lithium Americas Corp (NewCo) - Stock Price Chart
TickerLAC [NYSE]
CompanyLithium Americas Corp (NewCo)
CountryCanada
IndustryOther Industrial Metals & Mining
Market Cap588.60MEPS (ttm)-0.09
P/E-EPS this Y-343.54%
Forward P/E-EPS next Y-61.65%
PEG-EPS past 5Y40.15%
P/S-EPS next 5Y-
P/B0.89EPS Q/Q-186.92%
Dividend-Sales Q/Q-
Insider Own14.47%Inst Own19.08%
Insider Trans0.00%Inst Trans90.76%
Short Float13.69%EarningsAug 14/a
Analyst Recom2.00Target Price5.50
Avg Volume3.54M52W Range2.02 - 12.38
Lithium Americas Corp. owns and operates the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company is headquartered in Vancouver, Canada.
11014151617181920